Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice. - Test2 - elhamkhani - TriplyDB

Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice.

Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice.

http://www.wikidata.org/entity/Q37080167

about

Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice The regulatory role of DPP4 in atherosclerotic disease.Dipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells.The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3).Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide-induced lung injury by inhibiting endothelial-to-mesenchymal transition.AFM-based detection of glycocalyx degradation and endothelial stiffening in the db/db mouse model of diabetes.DPP-4 inhibition with linagliptin ameliorates the progression of premature aging in klotho-/- mice.Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke.Effect of linagliptin on pulse wave velocity in early type 2 diabetes: A randomized, double-blind, controlled 26-week trial (RELEASE).The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin.Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial.

P2860

Q33644666-C820F34F-AD92-4B51-8DF5-202FAFD279AD Q33805518-16B5A550-E30D-4BDD-8980-F23C21B56886 Q33883879-132778B3-EAC9-439C-A3D6-CD9D6B605937 Q42374104-9E7CEA68-615C-4E41-9D7F-A0F6454C8B80 Q42689842-CE423A2F-4319-49F5-850A-E5168141C765 Q45830225-DA8F50CB-3C10-4423-85D1-B5C33F0FA92C Q47148482-34ECE9A0-E60D-4777-B116-F0A03ADD3CC1 Q47156408-7DF1B005-FCED-4367-9153-F66DC25CCC3B Q48185907-994740E0-C790-4126-914C-D561BD15C497 Q52688968-87DB214A-322A-448C-8ED2-F8488641C6D6 Q52718518-FD9E0868-76F2-45A7-A368-2ACA8FE8B07D Q55002257-0A1339F2-F096-424B-821D-51C09DF0DF21

P2860

Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice.

http://www.wikidata.org/entity/Q37080167

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Dipeptidyl peptidase-4 inhibit ...... abnormalities in female mice.

@en

Dipeptidyl peptidase-4 inhibit ...... abnormalities in female mice.

@nl

type

label

Dipeptidyl peptidase-4 inhibit ...... abnormalities in female mice.

@en

Dipeptidyl peptidase-4 inhibit ...... abnormalities in female mice.

@nl

prefLabel

Dipeptidyl peptidase-4 inhibit ...... abnormalities in female mice.

@en

Dipeptidyl peptidase-4 inhibit ...... abnormalities in female mice.

@nl

P1433

Q37080167-92B73771-8687-4857-ABE0-334CF3935EB0

P1476

Q37080167-37109F0E-BD42-4A24-A5CE-41E9E134B1AF

P2093

Q37080167-0164BF5E-3F2E-4ACC-B522-3CB45AF22321

Q37080167-229D3C47-4E5C-4798-9E19-E214A23CE5EF

Q37080167-2A737F90-3F04-4DC9-B2B8-2BA9C57B57FA

Q37080167-32247ACD-C796-49E9-BF0B-B119EF0CC9F2

Q37080167-325DA53E-8069-49E8-86D9-83A34CD0D0F5

Q37080167-6E52A6D3-E123-40DE-8685-497132855414

Q37080167-93CE80C4-1AE1-4447-B9D1-39102CD5988F

Q37080167-AA7924CD-5564-433E-B813-D477D82C9DC4

Q37080167-D1778518-E74B-4AFF-B00C-FA8BFDA61DEF

Q37080167-EEB4FE72-43F8-4040-AFE4-F6E4FD2566F5

P2860

Q37080167-0A67C300-E71D-4CE1-92BD-5A6C706751AB

Q37080167-0E02CA37-929A-4429-97CB-B4EB245C2624

Q37080167-187169F3-5CBF-4105-B4EE-6C02FBF90662

Q37080167-19A8CFAE-4043-4564-A242-8CE35924E13D

Q37080167-1A3B196E-D882-4426-9187-760E12AF22F6

Q37080167-1E8E4869-06EE-4A2A-883E-DA57B318C752

Q37080167-2131604C-0219-401B-AE0B-07C830C7915F

Q37080167-22AEAE16-CC69-4A6F-94F1-DDFFBB4AB513

Q37080167-25B31E34-A904-402B-A13E-60AA3C6FB1E2

Q37080167-323FF7CF-4393-4256-9FDA-31136C52FCB5

P2888

Q37080167-31A54FCA-2E71-462E-A540-540C87E7CD30

P304

Q37080167-4393BD6E-8522-4952-A1EB-FE9E5350FAC0

P31

Q37080167-CCB1B491-9C9C-488B-B067-6CFC2532B37D

P356

Q37080167-7DE018E8-85F6-42A0-B4D6-1AF509807E78

P407

Q37080167-87D55155-F70D-4455-BBF4-E4C0B444C2E0

P478

Q37080167-D42972D1-6038-48C2-8538-6839AB5E2C9F

P50

Q37080167-307C7C0D-6753-4E8E-860D-798A987D27DB

P577

Q37080167-8E5F558B-8F51-483A-8206-A6246DE6F9D9

P6179

Q37080167-65FD8882-1615-400C-B7B0-3D2DC6A7AD1C

P698

Q37080167-E8A13665-2E1D-44DA-BF20-15236CA05587

P932

Q37080167-55FC5050-98E6-47B2-9437-B6ACA2F4C339

P356

S12933-016-0414-5

P1433

Cardiovascular Diabetology

P1476

Dipeptidyl peptidase-4 inhibit ...... abnormalities in female mice.

@en

P2093

Annayya R Aroor

http://www.w3.org/2001/XMLSchema#string

Camila Manrique

http://www.w3.org/2001/XMLSchema#string

Francisco I Ramirez-Perez

http://www.w3.org/2001/XMLSchema#string

Gerald A Meininger

http://www.w3.org/2001/XMLSchema#string

Guanghong Jia

http://www.w3.org/2001/XMLSchema#string

James R Sowers

http://www.w3.org/2001/XMLSchema#string

Javad Habibi

http://www.w3.org/2001/XMLSchema#string

Luis A Martinez-Lemus

http://www.w3.org/2001/XMLSchema#string

Melvin R Hayden

http://www.w3.org/2001/XMLSchema#string

Mona Garro

http://www.w3.org/2001/XMLSchema#string

P2860

Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies

8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes

Klotho converts canonical FGF receptor into a specific receptor for FGF23

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Potential Predictors of Plasma Fibroblast Growth Factor 23 Concentrations: Cross-Sectional Analysis in the EPIC-Germany Study

Obesity and insulin resistance induce early development of diastolic dysfunction in young female mice fed a Western diet.

Prevention of obesity-induced renal injury in male mice by DPP4 inhibition.

Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis.

P2888

s12933-016-0414-5

P304

94

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12933-016-0414-5

http://www.w3.org/2001/XMLSchema#string

P407

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Vincent G DeMarco

P577

2016-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1013487294

http://www.w3.org/2001/XMLSchema#string

P698

27391040

http://www.w3.org/2001/XMLSchema#string

P932

4938903

http://www.w3.org/2001/XMLSchema#string